Abstract:Background:A previous study on thymomas in myasthenia gravis (MG) patients indicated that OX40 expression may be upregulated in thymic tissues adjacent to germinal centers (GCs) and thymomas, and OX40 may interact with OX40L in GCs to enhance anti-acetylcholine receptor antibody production. However, little is known about the clinical significance of the expression of OX40 and OX40L in the peripheral blood of patients with MG. We aimed to characterize the expression of membrane-bound and soluble OX40 and OX40L in the peripheral blood of patients with MG and to identify their clinical significance.Methods:For membrane molecules, we collected peripheral blood (PB) from 39 MG patients at baseline, 22 patients in relapse, and 42 patients in remission, as well as from 36 healthy participants as controls. For soluble molecules, plasma from 37 MG patients at baseline, 34 patients in relapse, and 30 patients in remission, as well as plasma from 36 healthy controls (HC), was retrospectively collected from the sample bank of the First Hospital of Soochow University. The expression of membrane-bound OX40 and OX40L (mOX40 and mOX40L) by immune cells was measured using flow cytometry. Plasma levels of soluble OX40 and OX40L (sOX40 and sOX40L) were measured by ELISA.Results:(1) The expression of OX40 on CD4+ T cells and that of OX40L on B cells and monocytes were significantly increased, and the levels of sOX40 were significantly decreased in MG patients at baseline compared with HC, while the expression of sOX40L was not significantly different between the two groups. (2) Dynamic observation of the molecules showed significantly higher expression of OX40 on CD4+ T cells and higher levels of sOX40 in MG patients in relapse than in MG patients at baseline and MG patients in remission. Furthermore, the expression levels of sOX40 were significantly elevated in MG patients in remission compared with MG patients at baseline, and the expression of sOX40L was significantly lower in MG patients in remission than in MG patients at baseline and MG patients in relapse. (3) Plasma levels of sOX40 and sOX40L were significantly decreased in 13 patients with relapsed MG after immunosuppressive treatment compared with those before treatment. (4) Correlation analysis showed that the expression of OX40 on CD4+ T cells in patients with relapsed MG was positively correlated with the concentration of acetylcholine receptor antibodies (AchR-Ab), whereas the expression of OX40L on CD19+ B cells and CD14+ monocytes was negatively correlated with disease duration. (5) Binary regression analysis showed that patients with high CD4+ OX40 expression and high sOX40L levels had an increased risk of relapse.Conclusions:OX40 and OX40L are abnormally expressed in the peripheral blood of patients with MG and may be closely associated with disease status and treatment. The OX40/OX40L pathway may be involved in the immunopathological process of MG and may play a role mainly in the later stage of MG.

Circulating CD45RA-Foxp3++ Treg cells serve as a biomarker for predicting minimal clinical manifestations status of myasthenia gravis

Circulating Regulatory T Cells and B Cell-Activating Factor Receptor on B Cells in Patients with Myasthenia Gravis

Changes of Treg-Associated Molecules on CD4 + CD25 + Treg Cells in Myasthenia Gravis and Effects of Immunosuppressants

Decrease of CD4+CD25highFoxp3+ regulatory T cells and elevation of CD19+BAFF-R+ B cells and soluble ICAM-1 in myasthenia gravis

Imbalance of Circulating CD4+CXCR5+FOXP3+ Tfr-like Cells and CD4+CXCR5+FOXP3− Tfh-like Cells in Myasthenia Gravis

Comparison of Peripheral Blood Regulatory T Cells and Functional Subsets Between Ocular and Generalized Myasthenia Gravis (vol 9, 851808, 2022)

Increase of circulating CD4 +CD25 + T cells in myasthenia gravis patients with stability and thymectomy

Comparison of Peripheral Blood Regulatory T Cells and Functional Subsets Between Ocular and Generalized Myasthenia Gravis

Circulating Th1/17 cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients

Increased activated regulatory T cell subsets and aging Treg-like cells in multiple myeloma and monoclonal gammopathy of undetermined significance: a case control study

Circulating CXCR5+ natural killer cells are expanded in patients with myasthenia gravis

Changes of regulatory T cells in peripheral blood of patients with myasthenia gravis and the effect of immu-nosuppressive treatment

Comparison of Peripheral Blood B Cell Subset Ratios and B Cell-Related Cytokine Levels Between Ocular and Generalized Myasthenia Gravis.

Expression of Immune Molecules CD25 and CXCL13 Correlated with Clinical Severity of Myasthenia Gravis.

MicroRNA‑155‑5p Affects Regulatory T Cell Activation and Immunosuppressive Function by Targeting BCL10 in Myasthenia Gravis

Dynamic study of circulating CD_4~+CD_(25)~(high) T cells in myasthenia gravis

Regulatory B Cells Are Decreased and Functionally Impaired in Myasthenia Gravis Patients

The expression of co-stimulatory molecule OX40 on CD4~+T-cells and its' pathogenetic role in patients with myasthenia gravis

Effects of Follicular Helper T Cells and Inflammatory Cytokines on Myasthenia Gravis

Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis.

The abnormal mitophagy of regulatory T cells in peripheral blood of patients with myasthenia gravis